Exendin-4, an analogue of Glucagon-like peptide-1, attenuates hyperalgesia through serotonergic pathways in rats with neonatal colonic sensitivity

Journal of Physiology and Pharmacology

Volumn 65, Issue 3, 2014, Pages 349-357

  Yang, Y ^a   Cui, X ^a   Chen, Y ^b   Wang, Y ^a   Li, X ^a   Lin, L ^a   Zhang, H ^a  

^a THE FIRST AFFILIATED HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

^b TAISHAN MEDICAL UNIVERSITY   (China)

Author keywords

Glucagon like peptide 1; Irritable bowel syndrome; Serotonin transporter; Tryptophan hydroxylase 1; Visceral hypersensitivity

Indexed keywords

ACETIC ACID; EXENDIN 4; GLUCAGON LIKE PEPTIDE 1; MESSENGER RNA; SEROTONIN; SEROTONIN TRANSPORTER; TRYPTOPHAN HYDROXYLASE; TRYPTOPHAN HYDROXYLASE 1; UNCLASSIFIED DRUG; PEPTIDE; VENOM;

ABDOMINAL WITHDRAWAL REFLEX; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHEMOLUMINESCENCE; COLITIS; COLON INJURY; CONTROLLED STUDY; DOWN REGULATION; ELECTROMYOGRAPHY; ENZYME LINKED IMMUNOSORBENT ASSAY; HYPERALGESIA; HYPERSENSITIVITY; IRRITABLE COLON; MALE; NONHUMAN; PROTEIN EXPRESSION; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCORING SYSTEM; WESTERN BLOTTING; WITHDRAWAL REFLEX; ANIMAL; BLOOD; COLON; DRUG EFFECTS; METABOLISM; PATHOLOGY; SPRAGUE DAWLEY RAT;

ACETIC ACID; ANIMALS; COLON; HYPERALGESIA; MALE; PEPTIDES; RATS; RATS, SPRAGUE-DAWLEY; SEROTONIN; VENOMS;

EID: 84902511681     PISSN: 08675910     EISSN: 18991505     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Cremonini F, Talley NJ. Irritable bowel syndrome: epidemiology, natural history, health care seeking and emerging risk factors. Gastroenterol Clin North Am 2005; 34: 189-204.
2. Collins SM, Piche T, Rampal P. The putative role of inflammation in the irritable bowel syndrome. Gut 2001; 49: 743-745.
3. Heaton KW, Ghosh S, Braddon FE. How bad are the symptoms and bowel dysfunction of patients with the irritable bowel syndrome? A prospective, controlled study with emphasis on stool form. Gut 1991; 32: 73-79.
4. Hellstrom PM, Hein J, Bytzer P, Bjornsson E, Kristensen J, Schambye H. Clinical trial: the glucagon-like peptide-1 analogue ROSE-010 for management of acute pain in patients with irritable bowel syndrome: a randomized, placebo-controlled, double-blind study. Aliment Pharmacol Ther 2009; 29: 198-206.
5. Holst JJ. The physiology of glucagon-like peptide 1. Physiol Rev 2007; 87: 1409-1439.
6. Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP. Gastroenterology 2007; 132: 2131-2157.
7. Hellstrom PM, Naslund E, Edholm T, et al. GLP-1 suppresses gastrointestinal motility and inhibits the migrating motor complex in healthy subjects and patients with irritable bowel syndrome. Neurogastroenterol Motil 2008; 20: 649-659.
8. Schirra J, Nicolaus M, Roggel R, et al. Endogenous glucagon-like peptide 1 controls endocrine pancreatic secretion and antro-pyloro-duodenal motility in humans. Gut 2006; 55: 243-251.
9. Hellstrom PM, Smithson A, Stowell G, et al. Receptor-mediated inhibition of small bowel migrating complex by GLP-1 analog ROSE-010 delivered via pulmonary and ystemic routes in the conscious rat. Regul Pept 2012; 179: 71-76.
10. Tolessa T, Gutniak M, Holst JJ, Efendic S, Hellstrom PM. Inhibitory effect of glucagon-like peptide-1 on small bowel motility. Fasting but not fed motility inhibited via nitric oxide independently of insulin and somatostatin. J Clin Invest 1998; 102: 764-774.
11. Bullock BP, Heller RS, Habener JF. Tissue distribution of messenger ribonucleic acid encoding the rat glucagon-like peptide-1 receptor. Endocrinology 1996; 137: 2968-2978.
12. Rotondo A, Amato A, Lentini L, Baldassano S, Mule F. Glucagon-like peptide-1 relaxes gastric antrum through nitric oxide in mice. Peptides 2011; 32: 60-64.
13. Li ZY, Chen Y, Lin L, Wang MF, Hao B, Zhang HJ. Changes of serum glucagon-like peptide-1 receptor in rat models of irritable bowel syndrome subtypes. Chin J Dig 2012; 32: 249-255.
14. Camilleri M. Serotonergic modulation of visceral sensation: lower gut. Gut 2002; 51 (Suppl. 1): i81-i86.
15. Tack J, Sarnelli G. Serotonergic modulation of visceral sensation: upper gastrointestinal tract. Gut 2002; 51 (Suppl. 1): i77-i80.
16. Winston J, Shenoy M, Medley D, Naniwadekar A, Pasricha PJ. The vanilloid receptor initiates and maintains colonic hypersensitivity induced by neonatal colon irritation in rats. Gastroenterology 2007; 132: 615-627.
17. Xu GY, Shenoy M, Winston JH, Mittal S, Pasricha PJ. P2X receptor-mediated visceral hyperalgesia in a rat model of chronic visceral hypersensitivity. Gut 2008; 57: 1230-1237.
18. Appleyard CB, Wallace JL. Reactivation of hapten-induced colitis and its prevention by anti-inflammatory drugs. Am J Physiol 1995; 269: G119-G125.
19. Bojanowska E, Radziszewska E. Combined stimulation of glucagon-like peptide-1 receptor and inhibition of cannabinoid CB1 receptor act synergistically to reduce food intake and body weight in the rat. J Physiol Pharmacol 2011; 62: 395-402.
20. Chauveau J, Fert V, Morel AM, Delaage MA. Rapid and specific enzyme immunoassay of serotonin. Clin Chem 1991; 37: 1178-1184.
21. Konturek PC, Brzozowski T, Konturek SJ. Gut clock: implication of circadian rhythms in the gastrointestinal tract. J Physiol Pharmacol 2011; 62: 139-150.
22. Camilleri M, McKinzie S, Busciglio I, et al. Prospective study of motor, sensory, psychologic, and autonomic functions in patients with irritable bowel syndrome. Clin Gastroenterol Hepatol 2008; 6: 772-781.
23. Yan Chen, Zhengyang Li, Yan Yang, Lin Lin, Hongjie Zhang. Role of glucagon-like peptide-1 in the pathogenesis of experimental irritable bowel syndrome rat models. Int J Mol Med 2013; 31: 607-613.
24. Whitehead WE, Holtkotter B, Enck P, et al. Tolerance for rectosigmoid distention in irritable bowel syndrome. Gastroenterology 1990; 98: 1187-1192.
25. Bonaz B. Visceral sensitivity perturbation integration in the brain-gut axis in functional digestive disorders. J Physiol Pharmacol 2003; 54 (Suppl. 4): 27-42.
26. Cote F, Thevenot E, Fligny C, et al. Disruption of the nonneuronal tph1 gene demonstrates the importance of peripheral serotonin in cardiac function. Proc Natl Acad Sci USA 2003; 100: 13525-13530.
27. Walther DJ, Peter JU, Bashammakh S, et al. Synthesis of serotonin by a second tryptophan hydroxylase isoform. Science 2003; 299: 76.
28. Gutknecht L, Waider J, Kraft S, et al. Deficiency of brain 5-HT synthesis but serotonergic neuron formation in Tph2 knockout mice. J Neural Transm 2008; 115: 1127-1132.
29. Bulbring E, Lin RC. The effect of intraluminal application of 5-hydroxytryptamine and 5-hydroxytryptophan on peristalsis; the local production of 5-HT and its release in relation to intraluminal pressure and propulsive activity. J Physiol 1958; 140: 381-407.
30. Hillsley K, Kirkup AJ, Grundy D. Direct and indirect actions of 5-hydroxytryptamine on the discharge of mesenteric afferent fibres innervating the rat jejunum. J Physiol 1998; 506: 551-561.
31. Grundy D, Blackshaw LA, Hillsley K. Role of 5-hydroxytryptamine in gastrointestinal chemosensitivity. Dig Dis Sci 1994; 39 (Suppl. 12): 44S-47S.
32. Chen JJ, Li Z, Pan H, et al. Maintenance of serotonin in the intestinal mucosa and ganglia of mice that lack the high-affinity serotonin transporter: abnormal intestinal motility and the expression of cation transporters. J Neurosci 2001; 21: 6348-6361.
33. Wheatcroft J, Wakelin D, Smith A, Mahoney CR, Mawe G, Spiller R. Enterochromaffin cell hyperplasia and decreased serotonin transporter in a mouse model of postinfectious bowel dysfunction. Neurogastroenterol Motil 2005; 17: 863-870.
34. Coates MD, Mahoney CR, Linden DR, et al. Molecular defects in mucosal serotonin content and decreased serotonin reuptake transporter in ulcerative colitis and irritable bowel syndrome. Gastroenterology 2004; 126: 1657-1664.
35. Kerckhoffs AP, ter Linde JJ, Akkermans LM, Samsom M. SERT and TPH-1 mRNA expression are reduced in irritable bowel syndrome patients regardless of visceral sensitivity state in large intestine. Am J Physiol Gastrointest Liver Physiol 2012; 302: G1053-G1060.
36. Atkinson W, Lockhart S, Whorwell PJ, Keevil B, Houghton LA. Altered 5-hydroxytryptamine signaling in patients with constipation- and diarrhea-predominant irritable bowel syndrome. Gastroenterology 2006; 130: 34-43.
37. Chojnacki C, Walecka-Kapica E, Mokwinska M, et al. Influence of tianeptine on melatonin homeostasis and psychosomatic symptoms in patients with irritable bowel syndrome. J Physiol Pharmacol 2013; 64: 177-183.
38. Erspamer V. Occurrence and distribution of 5-hydroxytryptamine (enteramine) in the living organism. Z Vitam Horm Fermentforsch 1957; 9:74-96.